$PROF News
Last published 2d ago
- 2d agoPROFProfound Medical to Participate in the Stifel 2026 Healthcare ConferenceGlobeNewswireTORONTO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced that its President, Richard Fabian, will present at the Stifel 2026 Healthcare Conference on Thursday, November 12, 2026 at 8:40 a.m. Eastern Time ...
- 2d agoPROFProfound Medical to Participate in the Stifel 2026 Healthcare ConferenceGlobeNewswireTORONTO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative
- 6d agoPROFProfound Medical Corp. - PRESS RELEASEEarnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 6d agoPROFTLXProfound Medical Reports Strong Third Quarter 2026 Results; Expands U.S. Distribution and Positions Leadership for Next Phase of GrowthGlobeNewswireGross margin reaches 78%; cash used in operating activities declines 56% sequentially Profound expects full-year 2026 revenue to be at least $25.0 million; minimum gross margin projection for the year remains at 70% or
- 1w agoPROFProfound Medical and Cook Medical’s iMRI Division Partner to Expand U.S. TULSA-PRO® Sales Channels and Drive Recurring Revenue GrowthGlobeNewswireNew distribution agreement positions TULSA-PRO within the iMRI Suite offering through Cook Medical’s Copernicus™ program, expanding Profound’s commercial reach Profound retains direct TULSA-PRO recurring treatment kit
- 2w agoPROFEmmy-Award Winning Television Host Montel Williams to Join Next ‘Let’s Huddle’ WebinarGlobeNewswireTORONTO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company") today announced that Emmy Award-winning television host, health advocate and
- 4w agoPROFTULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion OpportunityGlobeNewswireTORONTO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company") today announced that five abstracts presented at the 15th Interventional MRI
- 1mo agoPROFTLXProfound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate CareGlobeNewswireCollaboration will educate physicians and prostate cancer centers on the complementary roles of Telix’s PSMA-PET molecular imaging technologies and Profound’s MRI-guided TULSA-PRO® Agreement provides Profound with
- 1mo agoPROFProfound Medical Reports Strong Preliminary Third Quarter 2026 RevenueGlobeNewswireTORONTO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative
- 2mo agoPROFProfound Medical to Participate in Lake Street’s 10th Annual Best Ideas Growth ConferenceGlobeNewswireTORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative
- 2mo agoPROFProfound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as PresidentGlobeNewswireTORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative
- 2mo agoPROFProfound’s Introduction of New Real-time Interventional MRI Software Paving the Way for Full ‘TULSA Days’GlobeNewswireTORONTO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative
- 2mo agoPROFProfound Medical Announces Management ChangeGlobeNewswireTORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative
- 3mo agoPROFProfound Medical Launches ‘Let's Huddle’, a Global Community Supporting Men Throughout Their Prostate Care JourneyGlobeNewswireTORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative
- 3mo agoPROFProfound Medical Reports Second Quarter 2026 Financial ResultsGlobeNewswire– Operating expenses decline 16%, helping drive a 39% improvement in net loss – – Approximately $3.1 million of TULSA revenue recognition shifts into early Q3 due to shipment timing – – Strong clinical, commercial and
- 3mo agoPROFProfound Medical to Release Second Quarter 2026 Financial Results on August 6th – Conference Call to FollowGlobeNewswireTORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative
- 3mo agoPROFProfound Medical: Autonomous Robotics and Incisionless Surgery to Have Exceptional Presence at SRS2026GlobeNewswireTORONTO, July 15, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company") is pleased to announce that its MRI-guided, AI-powered, Robotically-Driven and
- 6mo agoEDAPPROFTLXTelix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment ApproachesGlobeNewswireTelix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.Initial focus on patient selection, treatment planning and post-treatment monitoring;
- 6mo agoPROFProfound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026GlobeNewswireTORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI
- 6mo agoPROFProfound Medical Reports Strong First Quarter 2026 Financial ResultsGlobeNewswire– Quarterly results marked by 104% revenue growth and improved operating performance – – Company issues full-year 2026 revenue guidance – – Announces Humana is now covering the TULSA Procedure™ – TORONTO, May
- 6mo agoMDTDHRPROFDXCMWhy Medtech Giants Are Quietly Paying Up for AI DiagnosticsPR NewswireUSANewsGroup.com News Commentary – There's a quiet bidding war underway for AI diagnostics, and the price keeps climbing. The global AI in medical...
- 6mo agoPROFProfound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to FollowGlobeNewswireTORONTO, April 16, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided,
- 7mo agoPROFProfound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor ConferenceGlobeNewswireTORONTO, April 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided,
- 7mo agoPROFIncision-Free, MRI-Guided Prostate Treatment with Profound's TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific MeetingGlobeNewswireTORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided,
- 7mo agoPROFProfound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ MilestoneGlobeNewswireTORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided,
- 8mo agoPROFCAPTAIN Trial Comparing Profound's MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary ContinenceGlobeNewswire– First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment – – TULSA treatment demonstrates a
- 8mo agoPROFProfound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24GlobeNewswireTORONTO, March 09, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided,
- 8mo agoPROFProfound Medical Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireTORONTO, March 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI
- 9mo agoPROFProfound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th – Conference Call to FollowGlobeNewswireTORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI
- 9mo agoPROFProfound Medical Honored with INOVAIT's 2025–2026 Mount Logan Award Recognizing the TULSA Procedure™ for Prostate DiseaseGlobeNewswireTORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage innovator in interventional MRI ("iMRI") procedures, is pleased to announce
- 9mo agoPROFPRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women's HealthGlobeNewswireTORONTO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided,
- 9mo agoPROFProfound Medical Announces Upcoming Investor EventsGlobeNewswireTORONTO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided,
- 10mo agoPROFMount Sinai Becomes First in Metro New York to Deliver Incision-Free, MRI-Guided Prostate Treatment with TULSA-PRO®GlobeNewswireMount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexual function The Mount Sinai Hospital is ranked No. 6 nationally for Urology by US News & World Report® for
- 10mo agoPROFProfound Surpasses 2025 TULSA-PRO® Installed Base GoalGlobeNewswireTORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided,
- 10mo agoPROFProfound Medical Corp. Announces Closing of Private PlacementGlobeNewswireTORONTO, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company") is pleased to announce that it has completed its previously announced private placement of common
- 10mo agoPROFProfound Medical Corp. Announces Upsize of Private PlacementGlobeNewswireTORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company") is pleased to announce that it has increased the size of its private placement previously announced
- 10mo agoPROFProfound Medical Corp. Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30thGlobeNewswireTORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company") today announced the closing of its previously announced registered direct offering of 5,142,870
- 10mo agoPROFProfound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private PlacementGlobeNewswireTORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company") today announced the sale of 5,142,857 common shares at a purchase price of $7.00 per share in a
- 11mo agoPROFStanford Medicine's Dr. Pejman Ghanouni Receives RSNA's Cum Laude Award for CAPTAIN Perioperative Data PresentationGlobeNewswireTORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided,
- 11mo agoPROFProfound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO MeetingsGlobeNewswireTORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided,
- 11mo agoPROFProfound Medical Celebrates The Hong Center's 200th Independent TULSA Procedure for Prostate DiseaseGlobeNewswireTORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided,
- 12mo agoPROFProfound Medical Reports Strong Third Quarter 2025 Financial ResultsGlobeNewswireTORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided,
- 12mo agoPROFProfound Medical Announces Strategic Distribution Agreement with Getz Healthcare to Bring TULSA-PRO® to Australia and New ZealandGlobeNewswireTORONTO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided,
- 1y agoPROFProfound Medical Inks Exclusive Distribution Agreement for TULSA-PRO® and Sonalleve® with Al Faisaliah Medical Systems in Saudi ArabiaGlobeNewswireAgreement creates runway for Profound's incision-free and radiation-free therapies for the ablation of diseased tissue, to penetrate the largest healthcare market in the Middle East All required regulatory approvals to
- 1y agoPROFProfound Medical Regains Exclusive Distribution Rights for TULSA-PRO® in Canada from KnightGlobeNewswireTORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets artificial intelligence
- 1y agoPROFProfound Medical Congratulates the Busch Center for Achieving 500th TULSA Procedure MilestoneGlobeNewswireTORONTO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, AI-powered,
- 1y agoPROFProfound Medical to Participate in the Stifel 2025 Healthcare ConferenceGlobeNewswireTORONTO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, AI-powered,
- 1y agoPROFProfound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third QuarterGlobeNewswireTORONTO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, AI-powered,
- 1y agoPROFTexas Prostate and Dallas Medical Center Launch First-of-its-Kind TULSA Program, Expanding Access to Advanced Prostate TreatmentGlobeNewswireTORONTO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company developing AI-powered, incision-free therapies for
- 1y agoPROFProfound Medical to Participate in Lake Street's 9th Annual Best Ideas Growth ConferenceGlobeNewswireTORONTO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free